<DOC>
	<DOCNO>NCT01486875</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate incidence serious adverse drug reaction initiate insulin therapy NovoMix® 30 subject type 2 diabetes mellitus normal clinical practice condition Sweden .</brief_summary>
	<brief_title>Observational Study Safety NovoMix® 30 Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects type 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>